 |
50 Diseases |  |
11 Trials |
|
11 Trials |  |
833 News |  |
| «123456789101112 |
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open: RECAD-AF: Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients (clinicaltrials.gov) - Sep 4, 2013
P2, N=32, Recruiting, Sponsor: University of Utah
Not yet recruiting --> Recruiting
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress (clinicaltrials.gov) - Sep 2, 2013
P=N/A, N=12, Completed, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects (clinicaltrials.gov) - Aug 27, 2013
P1, N=36, Completed, Sponsor: Astellas Pharma Global Development, Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P4 trial: Characterization of Myocardial Blood Flow Measurements Using Lexiscan (clinicaltrials.gov) - Aug 7, 2013
P4, N=60, Recruiting, Sponsor: Timothy M. Bateman, MD
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P1 trial: Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects (clinicaltrials.gov) - Aug 6, 2013
P1, N=36, Completed, Sponsor: Astellas Pharma Global Development, Inc.
- || Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment closed: Lexi-Echo: Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography (clinicaltrials.gov) - Jun 5, 2013
P=N/A, N=380, Active, not recruiting, Sponsor: Aiden Abidov
Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open: A Phase II Trial of Regadenoson in Sickle Cell Anemia (clinicaltrials.gov) - May 12, 2013
P2, N=96, Recruiting, Sponsor: Dana-Farber Cancer Institute
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P2 trial: Phase Analysis and Obstructive CAD on Rubidium PET (clinicaltrials.gov) - Apr 24, 2013
P2, N=50, Recruiting, Sponsor: Emory University
- ||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open: RVuptakeLexi: Stress Induced Right Ventricular Uptake on Lexiscan Stress MPI (clinicaltrials.gov) - Apr 6, 2013
P=N/A, N=650, Enrolling by invitation, Sponsor: Aiden Abidov
Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease (clinicaltrials.gov) - Mar 31, 2013
P1, N=39, Completed, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Enrolling by invitation Recruiting --> Completed
- || Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P3 trial: Regadenoson and Adenosine (clinicaltrials.gov) - Mar 11, 2013
P3, N=100, Completed, Sponsor: Lokien van Nunen
- || Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment change: Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging (clinicaltrials.gov) - Feb 20, 2013
P=N/A, N=120, Completed, Sponsor: University of Chicago
Recruiting --> Completed N=160 --> 120
- ||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging (clinicaltrials.gov) - Feb 20, 2013
P=N/A, N=120, Completed, Sponsor: University of Chicago
N=160 --> 120 Recruiting --> Completed
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P2 trial: A Phase II Trial of Regadenoson in Sickle Cell Anemia (clinicaltrials.gov) - Feb 7, 2013
P2, N=96, Recruiting, Sponsor: Dana-Farber Cancer Institute
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P4 trial: Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson (clinicaltrials.gov) - Jan 28, 2013
P4, N=15, Recruiting, Sponsor: Washington University School of Medicine
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P2 trial: RECAD-AF: Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients (clinicaltrials.gov) - Oct 17, 2012
P2, N=32, Recruiting, Sponsor: University of Utah
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open: Regadenoson Real Time Perfusion Imaging Trial-Optison (clinicaltrials.gov) - Sep 24, 2012
P=N/A, N=50, Recruiting, Sponsor: Thomas R. Porter, MD
Recruiting --> Completed Not yet recruiting --> Recruiting
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial initiation date: Regadenoson Real Time Perfusion Imaging Trial-Optison (clinicaltrials.gov) - Sep 18, 2012
P=N/A, N=50, Recruiting, Sponsor: Thomas R. Porter, MD
Not yet recruiting --> Recruiting Initiation date: Dec 2011 --> Sep 2012
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P4 trial: ASSUAGE-MPI: The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion (clinicaltrials.gov) - Jul 31, 2012
P4, N=60, Suspended, Sponsor: Rush University Medical Center
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P2 trial: Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI (clinicaltrials.gov) - Jul 30, 2012
P2, N=20, Not yet recruiting, Sponsor: Northwestern University
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion, Adverse events: ASSUAGE-CKD: Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging (clinicaltrials.gov) - Jul 25, 2012
P4, N=300, Completed, Sponsor: Rush University Medical Center
Initiation date: Dec 2011 --> Sep 2012 Recruiting --> Completed
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Regadenoson R-T Perfusion Imaging Trial (clinicaltrials.gov) - Jul 18, 2012
P=N/A, N=100, Completed, Sponsor: University of Nebraska
Recruiting --> Completed Active, not recruiting --> Completed
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial initiation date: Microvascular Blood Flow in Sickle Cell Anemia (clinicaltrials.gov) - Jul 16, 2012
P=N/A, N=103, Recruiting, Sponsor: Blood Center of Wisconsin
Active, not recruiting --> Completed Initiation date: Apr 2012 --> Jul 2012
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open: Microvascular Blood Flow in Sickle Cell Anemia (clinicaltrials.gov) - Jul 16, 2012
P=N/A, N=103, Recruiting, Sponsor: Blood Center of Wisconsin
Initiation date: Apr 2012 --> Jul 2012 Not yet recruiting --> Recruiting
- |||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT) (clinicaltrials.gov) - Jul 11, 2012
P2, N=124, Completed, Sponsor: Astellas Pharma Inc
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P3 trial: EXERRT: A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT) (clinicaltrials.gov) - Jun 11, 2012
P3, N=1147, Active, not recruiting, Sponsor: Astellas Pharma Global Development, Inc.
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment change: Stress Echocardiography Study With Regadenoson (clinicaltrials.gov) - May 6, 2012
P2, N=22, Terminated, Sponsor: Gilead Sciences
Active, not recruiting --> Completed N=40 --> 22
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion, MRI: Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson (clinicaltrials.gov) - Apr 7, 2012
P0, N=50, Completed, Sponsor: Washington University School of Medicine
N=40 --> 22 Recruiting --> Completed
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial initiation date: Intravenous Regadenoson Versus Intravenous Adenoscan (clinicaltrials.gov) - Mar 27, 2012
P=N/A, N=48, Recruiting, Sponsor: Ochsner Health System
Recruiting --> Completed Initiation date: Dec 2011 --> Mar 2012
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open: Intravenous Regadenoson Versus Intravenous Adenoscan (clinicaltrials.gov) - Mar 27, 2012
P=N/A, N=48, Recruiting, Sponsor: Ochsner Health System
Initiation date: Dec 2011 --> Mar 2012 Not yet recruiting --> Recruiting
- ||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging (clinicaltrials.gov) - Feb 29, 2012
P=N/A, N=140, Completed, Sponsor: Hartford Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D) (clinicaltrials.gov) - Feb 14, 2012
P4, N=26, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Completed Enrolling by invitation --> Completed
- || Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment change: Lexi-Echo: Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography (clinicaltrials.gov) - Dec 22, 2011
P=N/A, N=380, Active, not recruiting, Sponsor: Aiden Abidov
Enrolling by invitation --> Completed N=253 --> 380
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion, Adverse events: ASSUAGE: Study With Aminophylline to Attenuate of the Side Effects of Regadenoson (clinicaltrials.gov) - Oct 16, 2011
P4, N=248, Completed, Sponsor: Rush University Medical Center
N=253 --> 380 Active, not recruiting --> Completed
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P4 trial: Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease (clinicaltrials.gov) - Oct 2, 2011
P4, N=50, Recruiting, Sponsor: The Methodist Hospital System
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P1 trial: Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers (clinicaltrials.gov) - Sep 12, 2011
P1, N=145, Recruiting, Sponsor: University of Michigan